Latest Advisory

  • FDA Advisory No. 2016-144-A || Babala sa Publiko Tungkol sa Paggamit ng Hindi Rehistradong Gamot na “Sevelamer Hydrochloride (Sevel) 400 mg Tablet” na gawa ng The ACME Laboratories Ltd. – Dhaka, Bangladesh

    FDA Advisory No. 2016-144-A || Babala sa Publiko Tungkol sa Paggamit ng Hindi Rehistradong Gamot na “Sevelamer Hydrochloride (Sevel) 400 mg Tablet” na gawa ng The ACME Laboratories Ltd. – Dhaka, Bangladesh

    Read more

  • FDA Advisory No. 2016-144 || Public Health Warning Against the Use of the Unregistered Drug Product “Sevelamer Hydrochloride (Sevel) 400 mg Tablet” manufactured by The ACME Laboratories Ltd. – Dhaka, Bangladesh

    FDA Advisory No. 2016-144 || Public Health Warning Against the Use of the Unregistered Drug Product “Sevelamer Hydrochloride (Sevel) 400 mg Tablet” manufactured by The ACME Laboratories Ltd. – Dhaka, Bangladesh

    Read more

  • FDA Advisory No. 2016-143-A || Babala sa Publiko Tungkol sa Paggamit ng Hindi Rehistradong Gamot na “Puritan’s Pride Premium Folic Acid 400 mcg Tablet”

    FDA Advisory No. 2016-143-A || Babala sa Publiko Tungkol sa Paggamit ng Hindi Rehistradong Gamot na “Puritan’s Pride Premium Folic Acid 400 mcg Tablet”

    Read more

  • FDA Advisory No. 2016-143 || Public Health Warning Against the Use of the Unregistered Drug Product “Puritan’s Pride Premium Folic Acid 400 mcg Tablet”

    FDA Advisory No. 2016-143 || Public Health Warning Against the Use of the Unregistered Drug Product “Puritan’s Pride Premium Folic Acid 400 mcg Tablet”

    Read more

  • FDA Advisory No. 2016-142-A || Babala sa Publiko Tungkol sa Paggamit ng mga Hindi Rehistradong Gamot na:

    FDA Advisory No. 2016-142-A || Babala sa Publiko Tungkol sa Paggamit ng mga Hindi Rehistradong Gamot na:

    Read more

  • FDA Advisory No. 2016-142 || Public Health Warning Against the Use of the Following Unregistered Drug Products:

    FDA Advisory No. 2016-142 || Public Health Warning Against the Use of the Following Unregistered Drug Products:

    Read more

  • FDA Advisory No. 2016-141-A || Babala sa Publiko tungkol sa Paggamit ng mga Pekeng Gamot na:

    FDA Advisory No. 2016-141-A || Babala sa Publiko tungkol sa Paggamit ng mga Pekeng Gamot na:

    Read more

  • FDA Advisory No. 2016-141 || Public Health Warning Against the Use of the Following Counterfeit Drug Product:

    FDA Advisory No. 2016-141 || Public Health Warning Against the Use of the Following Counterfeit Drug Product:

    Read more

  • FDA Advisory No. 2016-140-A || Babala sa Publiko Tungkol sa Paggamit ng Pekeng Albumin (Human) U.S.P. Human Albumin Grifols 25% Solution “Manufactured by Instituto Grifols, S.A., Barcelona, Spain”

    FDA Advisory No. 2016-140-A || Babala sa Publiko Tungkol sa Paggamit ng Pekeng Albumin (Human) U.S.P. Human Albumin Grifols 25% Solution “Manufactured by Instituto Grifols, S.A., Barcelona, Spain”

    Read more

  • FDA Advisory No. 2016-140 || Public Health Warning Against the Use of the Counterfeit Albumin (Human) U.S.P. Human Albumin Grifols 25% Solution “Manufactured by Instituto Grifols, S.A., Barcelona, Spain”

    FDA Advisory No. 2016-140 || Public Health Warning Against the Use of the Counterfeit Albumin (Human) U.S.P. Human Albumin Grifols 25% Solution “Manufactured by Instituto Grifols, S.A., Barcelona, Spain”

    Read more

  • FDA Advisory No. 2016-133-A || Babala sa Publiko Tungkol sa Paggamit ng Hindi Rehistradong Gamot na:

    FDA Advisory No. 2016-133-A || Babala sa Publiko Tungkol sa Paggamit ng Hindi Rehistradong Gamot na:

    Read more

  • FDA Advisory No. 2016-133 || Public Health Warning Against the Use of the Following Unregistered Drug Product:

    FDA Advisory No. 2016-133 || Public Health Warning Against the Use of the Following Unregistered Drug Product:

    Read more

  • FDA Advisory No. 2016-139-A || Babala sa Publiko Tungkol sa Paggamit ng Hindi Rehistradong Gamot na “Curing Pill”

    FDA Advisory No. 2016-139-A || Babala sa Publiko Tungkol sa Paggamit ng Hindi Rehistradong Gamot na “Curing Pill”

    Read more

  • FDA Advisory No. 2016-139 || Public Health Warning Against the Use of the Unregistered Drug Product “Curing Pill”

    FDA Advisory No. 2016-139 || Public Health Warning Against the Use of the Unregistered Drug Product “Curing Pill”

    Read more

  • FDA Advisory No. 2016-138-A || Babala sa Publiko Tungkol sa Paggamit ng Hindi Rehistradong Gamot na “Double J Go Shi Ashitaba + Guyabano (Angelica Keskei + Soursop) Liniment”

    FDA Advisory No. 2016-138-A || Babala sa Publiko Tungkol sa Paggamit ng Hindi Rehistradong Gamot na “Double J Go Shi Ashitaba + Guyabano (Angelica Keskei + Soursop) Liniment”

    Read more

  • FDA Advisory No. 2016-138 || Public Health Warning Against the Use of the Unregistered Drug Product “Double J Go Shi Ashitaba + Guyabano (Angelica Keskei + Soursop) Liniment”

    FDA Advisory No. 2016-138 || Public Health Warning Against the Use of the Unregistered Drug Product “Double J Go Shi Ashitaba + Guyabano (Angelica Keskei + Soursop) Liniment”

    Read more

  • FDA Advisory No. 2016-137-A || Babala sa Publiko Tungkol sa Paggamit ng Hindi Rehistradong Gamot na:

    FDA Advisory No. 2016-137-A || Babala sa Publiko Tungkol sa Paggamit ng Hindi Rehistradong Gamot na:

    Read more

  • FDA Advisory No. 2016-137 || Public Health Warning Against the Use of the Following Unregistered Drug Products:

    FDA Advisory No. 2016-137 || Public Health Warning Against the Use of the Following Unregistered Drug Products:

    Read more

  • FDA Advisory No. 2016-136-A || Babala sa Publiko Tungkol sa Paggamit ng Hindi Rehistradong Gamot na “Jinling Bao Ji Pill”

    FDA Advisory No. 2016-136-A || Babala sa Publiko Tungkol sa Paggamit ng Hindi Rehistradong Gamot na “Jinling Bao Ji Pill”

    Read more

  • FDA Advisory No. 2016-136 || Public Health Warning Against the Use of the Unregistered Drug Product “Jinling Bao Ji Pill”

    FDA Advisory No. 2016-136 || Public Health Warning Against the Use of the Unregistered Drug Product “Jinling Bao Ji Pill”

    Read more

FDA Circular No. 2014-008-A

Amendment to Annex B, Notification for Minor of FDA Circular No. 2014-008 entitled "Application Process and Requirements for Post-Approval Changes of Pharmaceutical Products", Specially on Section IV, C, D, and E for Minor variation-Notification

Share Us on

Submit to FacebookSubmit to Google PlusSubmit to Twitter